CoChat

CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy

Published version of a preprint

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Accumulating evidence indicates that CD8+ T cells in the tumor microenvironment and systemic CD4+ T-cell immunity play an important role in mediating durable antitumor responses. We longitudinally examined T-cell immunity in the peripheral blood of patients with non–small lung cancer and found that responders had significantly (P < 0.0001) higher percentages of effector, CD62Llow CD4+ T cells prior to PD-1 blockade. Conversely, the percentage of CD25+FOXP3+ CD4+ T cells was significantly (P = 0.034) higher in nonresponders. We developed a formula, which demonstrated 85.7% sensitivity and 100% specificity, based on the percentages of CD62Llow CD4+ T cells and CD25+FOXP3+ cells to predict nonresponders. Mass cytometry analysis revealed that the CD62Llow CD4+ T-cell subset expressed T-bet+, CD27−, FOXP3−, and CXCR3+, indicative of a Th1 subpopulation. CD62Llow CD4+ T cells significantly correlated with effector CD8+ T cells (P = 0.0091) and with PD-1 expression on effector CD8+ T cells (P = 0.0015). Gene expression analysis revealed that CCL19, CLEC-2A, IFNA, IL7, TGFBR3, CXCR3, and HDAC9 were preferentially expressed in CD62Llow CD4+ T cells derived from responders. Notably, long-term responders, who had >500-day progression-free survival, showed significantly higher numbers of CD62Llow CD4+ T cells prior to PD-1 blockade therapy. Decreased CD62Llow CD4+ T-cell percentages after therapy resulted in acquired resistance, with long-term survivors maintaining high CD62Llow CD4+ T-cell percentages. These results pave the way for new treatment strategies for patients by monitoring CD4+ T-cell immune statuses in their peripheral blood.

Overview

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-19-0574

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Cited by

See all 264

Metadata

Authors
Kagamu, H., Kitano, S., Yamaguchi, O., Yoshimura, K., Horimoto, K., Kitazawa, M., Fukui, K., Shiono, A., Mouri, A., Nishihara, F., Miura, Y., Hashimoto, K., Murayama, Y., Kaira, K., & Kobayashi, K.
Affiliations
  • Saitama International Medical Center (JP)
  • Kanazawa University (JP)
  • National Institute of Advanced Industrial Science and Technology (JP)
Venue
Cancer Immunology Research
Published
2020-03-01
Volume
8
Issue
3
Pages
334-344
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2995822774
Cited by
256
References
41
Citations by year
2026: 20 · 2025: 26 · 2024: 62 · 2023: 39 · 2022: 46 · 2021: 40 · 2020: 23
FWCI
11.40
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Japan Agency for Medical Research and Development (18ae0101016s0105, 19ae0101074h0001)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
CD4+ T cells, anti-PD-1 therapy, non-small cell lung cancer, immune checkpoint inhibitor response prediction, Th1 cells, CD8+ effector T cells, PD-1 expression, acquired resistance, gene expression profiling, CCL19, CXCR3, HDAC9, IL-7, TGFBR3, progression-free survival, immune monitoring
MeSH terms
Antineoplastic Agents, Immunological, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Follow-Up Studies, Humans, Leukocytes, Mononuclear, Lung Neoplasms, Male, Middle Aged, Prognosis, CD4-Positive T-Lymphocytes, Survival Rate, T-Lymphocyte Subsets, Gene Expression Profiling, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. https://app.cochat.ai/papers/10.1158/2326-6066.cir-19-0574
The paper
Kagamu, H., Kitano, S., Yamaguchi, O., Yoshimura, K., Horimoto, K., Kitazawa, M., Fukui, K., Shiono, A., Mouri, A., Nishihara, F., Miura, Y., Hashimoto, K., Murayama, Y., Kaira, K., & Kobayashi, K. (2020). CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-19-0574

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.